Aesthetic pathway
KLOW
GHK-Cu, BPC-157, TB-500 & KPV
Laboratory verification
Nothing unverified is published
Every compound is prepared to a documented standard. Independent certificates of analysis are published here per batch as they are verified under Nuragen's own governance, we do not reuse another brand's certificates or purity figures.
Certificate of analysis · per batch · on request
Verification-led release
KLOW is a research-use-only blend of four peptides, GHK-Cu, BPC-157, TB-500 and KPV, grouped for study within the aesthetic and tissue-repair pathway. It is a laboratory reference material, not a treatment.
How it is studied
KLOW is examined in the research literature as a combined preparation, where investigators look at how its four constituent peptides behave together in laboratory and preclinical models. Studies of the individual components tend to focus on signalling associated with tissue remodelling, extracellular-matrix activity and inflammatory pathways. As a blend, it is handled as a single reference item for controlled experimental work rather than as separately dosed agents. All such work sits within a research setting.
What the components are and the pathway
The blend combines GHK-Cu, a copper-binding tripeptide studied in relation to matrix and collagen signalling; BPC-157, a peptide researched for its association with tissue-repair pathways; TB-500, a fragment linked in the literature to actin regulation and cell migration; and KPV, a short peptide studied for its association with inflammatory signalling. Together these sit within what is described here as the aesthetic pathway, a research grouping centred on skin quality and repair mechanisms. Each is characterised by the pathway it is thought to act on, not by any outcome.
How it sits in a responsible research programme
Within a structured programme, a multi-component material like KLOW is typically catalogued, logged and stored under defined conditions before any experimental use. Because it combines four peptides, documentation of identity and provenance is part of responsible handling. NURAGEN supplies KLOW as a research reference material only, with process and pathway information rather than instructions for use. Interpretation of any findings remains the responsibility of the qualified researcher.
Composition
| Component | CAS | Purity |
|---|---|---|
| GHK-Cu | 49557-75-7 | Pending |
| BPC-157 | 137525-51-0 | Pending |
| TB-500 | 77591-33-4 | Pending |
| KPV | 67727-97-3 | Pending |
| Type | Lyophilised powder |
|---|---|
| Presentation | Lyophilised powder |
| Appearance | White lyophilised powder |
| Storage | Store at 2-8°C, protected from light. |
| Dispatch | Delivered within 72 hours across the UK. |
Handling should follow standard laboratory practice and your own institutional protocols. No dosing, administration or medical guidance is provided.
KLOW is a research-use-only blend of four peptides, GHK-Cu, BPC-157, TB-500 and KPV, supplied as a laboratory reference material. It is intended solely for controlled research and is not a medicine, treatment or product for human or animal use.
As a general laboratory practice for peptide materials, storage at 2-8°C and protection from light are commonly specified to support stability. Handling should follow your own laboratory's standard operating procedures and the documentation accompanying the material.
No. NURAGEN provides scientific and pathway information only. We do not supply dosing, administration or medical advice, and none should be inferred. Any experimental parameters are determined by the qualified researcher within an appropriate research framework.
KLOW groups four peptides that are each studied within repair and skin-quality research, GHK-Cu, BPC-157, TB-500 and KPV. Combining them into one reference material allows researchers to study the constituents together in a single preparation. The blend is characterised by the pathways its components are thought to act on, not by any claimed result.
In context
Evidence before action
Combination materials such as KLOW carry an added layer of complexity: the published literature on each peptide is separate, and the way four compounds interact in a single preparation is its own research question. Reading the evidence base for GHK-Cu, BPC-157, TB-500 and KPV individually, and noting where blend-level data is limited, is part of careful study design. Evidence-led practice means characterising what is known, acknowledging what is not, and letting the research context, rather than expectation, guide interpretation.
Related pathways
Explore alongside
Aesthetic
Glow
Research-use blend of BPC-157, TB-500 and GHK-Cu studied in skin-repair pathways.
£170
Aesthetic
Skin Renewal
GHK-Cu copper peptide studied in collagen synthesis and tissue remodelling. Research use only.
£100
Recovery
Repair
A focused research pair of BPC-157 and TB-500, studied within tissue-repair pathways.
£140
Recovery
Wolverine
Proprietary recovery-pathway blend of tissue-repair and remodelling peptides, held for research use.
£170